The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Pathways in pulmonary arterial hypertension: the future is here
Open accessAbstract
It is well established that the endothelin, nitric oxide and prostacyclin pathways play an important role in the development of pulmonary arterial hypertension (PAH). Indeed, the therapeutic options currently available for the management of PAH all act on one of these mechanistic pathways. However, this is an exciting time for both clinicians and scientists, as increased understanding of the mechanisms involved in the pathogenesis and progression of PAH has resulted in the development of a number of novel therapeutic options. This article highlights how the introduction of new compounds such as macitentan, riociguat and selexipag, which act on the endothelin, nitric oxide and prostacyclin pathways, respectively, have the potential to further improve the prognosis for patients with PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathologically, all types of PH develop via an early, common vasculopathy driven by disproportionate pulmonary vasoconstriction and dramatic remodeling of the endothelium and vessel wall[5,26,27].”
From Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health (2017) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.
Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E., & Chaudhuri, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9265 · Cited by 5,074
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466
Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R. D., Shennib, H., Kimura, S., Masaki, Τ., Duguid, W. P., & Stewart, D. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282402 · Cited by 1,838
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,724
Arnold, W. P., Mittal, C. K., Katsuki, S., & Murad, F. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.8.3203 · Cited by 1,459
Christman, B. W., McPherson, C. D., Newman, J. H., King, G. A., Bernard, G. R., Groves, B. Μ., & Loyd, J. E. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270202 · Cited by 1,182
Tadalafil Therapy for Pulmonary Arterial Hypertension
Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.839274 · Cited by 1,096
Reversal of experimental pulmonary hypertension by PDGF inhibition
SCHERMULY, R. T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24838 · Cited by 1,080
Tuder, R. M., Cool, C. D., Geraci, M. W., Wang, J., Abman, S. H., Wright, L. A., Badesch, D. B., & Voelkel, N. F. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.6.9804054 · Cited by 804
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 667
Research works printed but not linked: 1
- Sidharta, 2010, Investigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjects, Br J Clin Pharmacol, 70, 730
Cited by
Sorted by citations
Items 101–117 of 117
Beyond Vasodilator: Anti-Apoptotic Effect of Endothelin Receptor Antagonist
Chang, S. (2014) · Korean Circulation Journal · doi:10.4070/kcj.2014.44.2.74
Childhood Pulmonary Arterial Hypertension
Krishnan, U., & Rosenzweig, E. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44887-1.00035-3
Nadciśnienie płucne – postępy w diagnostyce i leczeniu
Konopka, M. A., & Braksator, W. (2013) · Family Medicine & Primary Care Review
Whatever Happened to Oral Monotherapy?
Lee, J. J., Llanos, A., & Channick, R. W. (2017) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-15.4.190
Molecular Risk Factors of Pulmonary Arterial Hypertension
Assaggaf, H. M. (2017) · doi:10.25148/etd.fidc004013
Капустник, В. А., & Архіпкіна, О. Л. (2018) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2018-1-2-143-125-129
DIFFICULT DIAGNOSIS: IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION, CASE STUDY
Balla, E., Тауб, Г. С., Shachnjuk, N. E., & Petrashevich, A. V. (2018) · Journal of the Grodno State Medical University · doi:10.25298/2221-8785-2018-16-2-218-222
Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated
Bogaard, H. J., & Sitbon, O. (2021) · European Respiratory Journal · doi:10.1183/13993003.04258-2020
Вишнева, Е. М., & Егорова, Е. А. (2021) · Естественные и Технические Науки · doi:10.37882/2223-2966.2021.04-2.04
Cardiopulmonary Monitoring of Patients with Pulmonary Hypertension and Right Ventricular Failure
Davey, R., Alohali, A. F., Jia, S., & Mehta, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-73387-2_54
Adenosine A2A Receptor as a Target of Treatment for Pulmonary Arterial Hypertension.
de Alencar, N., & Kardec, A. (2014)
(2018) · International Journal of Biology Pharmacy and Allied Sciences · doi:10.31032/ijbpas/2018/7.12.4598
Bik, M. A., Onmaz, D. E., Gharab, K. M. K., Karaman, F., Abuşoğlu, S., Sivrikaya, A., & Ünlü, A. (2024) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-024-01215-x
IDIOPATHIC PULMONARY HYPERTENSION
Tsareva, N. A. (2024) · doi:10.18093/978-5-6048754-6-9-2024-2-406-420
Étude de la physiopathologie des formes héritable et induite d'hypertension pulmonaire
Abdoulkarim, B. S. (2022) · theses.fr (ABES) · doi:10.70675/298c697bz02a6z4e33zb1f6zccd05cab6f7c
Eczema-like cutaneous lesions in idiopathic pulmonary fibrosis: a shared Th2-driven pathway?
Pezzuto, A., Demofonte, I., Parisella, F. R., Luzi, F., Marco, G. D., & Tammaro, A. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3718
Ahmed, M., Zal, A., Zahiri, Z., Meshkati, H., Ashraf, H., Hassan, E. M. A. N., Jain, H., Ahmed, F., Chigurupati, H. D., & Neppala, S. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002194
Metadata
- Authors
- Sitbon, O., & Morrell, N.
- Affiliations
- Université Paris-Sud (FR)
- ORCID
- Sitbon, Olivier
- Venue
- European Respiratory Review
- Publisher
- European Respiratory Society (ERS)
- Published
- 2012-11-30
- Volume
- 21
- Issue
- 126
- Pages
- 321-327
- ISSN
- 0905-9180 (ISSN-L)
- 1600-0617
- PMC
- PMC9487224
- OpenAlex
- W2163323710
- Cited by
- 117
- References
- 59
- Citations by year
- 2026: 3 · 2024: 6 · 2023: 2 · 2022: 7 · 2021: 14 · 2020: 3 · 2019: 8 · 2018: 10 · 2017: 8 · 2016: 12 · 2015: 10 · 2014: 21 · 2013: 11 · 2012: 1
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- European Respiratory Review (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Actelion Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- pulmonary arterial hypertension, endothelin pathway, nitric oxide pathway, prostacyclin pathway, macitentan, riociguat, selexipag, PAH therapy, endothelin receptor antagonists, soluble guanylate cyclase stimulator, prostacyclin analogues
- MeSH terms
- Imatinib Mesylate, Acetamides, Animals, Antihypertensive Agents, Benzamides, Clinical Trials as Topic, Guanylate Cyclase, Humans, Hypertension, Pulmonary, Lisuride, Nitric Oxide, Piperazines, Epoprostenol, Pyrazines, Pyrazoles, Pyrimidines, Serotonin Antagonists, Sulfonamides, Drugs, Investigational, Endothelin-1, Protein Kinase Inhibitors, Phosphodiesterase 5 Inhibitors, Endothelin A Receptor Antagonists, Endothelin B Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
